Abstract 1688P
Background
Elderly patients are disproportionately burdened with cancer morbidity and mortality. The disease and its treatment are complicated by ageing-related issues such as loss of loved ones, socioeconomic changes, and the presence of comorbidities. Thus, they are at high risk of psychosocial distress and poor health-related quality of life. There is a significant paucity of data on the prevalence and determinants of psychosocial distress among elderly patients with cancer in Nigeria, necessitating this study.
Methods
This descriptive cross-sectional study was conducted among 296 patients aged 60 years and older with cancer attending the NSIA LUTH Cancer Centre. Data collection was interviewer-based using a structured questionnaire along with the Depression, Anxiety, and Stress Scale 21-item (DASS-21) and Functional Assessment of Chronic Illness Therapy—Spiritual Well-Being 12 (FACITsp-12). The association between different variables was assessed by chi square. Statistical analysis was done with IBM Statistical Package for Social Sciences Version 25, and a p value of <0.05 was regarded as significant.
Results
The prevalence of psychosocial distress among the respondents was depression (19.9%), anxiety (46.0%), and stress (3.0%). The majority of the respondents (77.7%) had intermediate/high spiritual levels. The prevalence of depression was significantly higher in those with comorbidities and those receiving chemotherapy. A high spiritual level was also significantly associated with a lower level of depression, anxiety, and stress.
Conclusions
We found a higher prevalence of psychosocial distress among patients who received chemotherapy as part of their treatment and also among those with comorbidities. A higher spiritual level was found to be associated with a reduced level of psychosocial distress. Therefore, there is a need to screen patients with comorbidities and those on chemotherapy for psychosocial distress in order to identify those in need of additional psychological and social work support. A holistic approach that integrates psychosocial and spiritual care into cancer treatment not only alleviates the emotional burden but also contributes to improved overall well-being and treatment outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. A. Ogunjimi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1686P - Raising the unheard voices of cancer caregivers in Asia: Comparative and sociodemographic analysis on quality of life
Presenter: Muhammad Alifian Putra
Session: Poster session 11
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11